share_log

Pfizer | 8-K: Pfizer Announced That It Is Beginning the Process of Finding a Successor for Dr. Mikael Dolsten

Pfizer | 8-K: Pfizer Announced That It Is Beginning the Process of Finding a Successor for Dr. Mikael Dolsten

輝瑞 | 8-K:輝瑞宣佈正在開始爲Mikael Dolsten博士尋找繼任者
美股sec公告 ·  07/10 16:15
Moomoo AI 已提取核心訊息
Pfizer Inc. has announced the commencement of a search for a new Chief Scientific Officer as Dr. Mikael Dolsten, the current Chief Scientific Officer and President of Pfizer Research & Development, prepares to step down. Dr. Dolsten, who has had a notable career spanning over 15 years at Pfizer, will remain in his role until a successor is appointed and a proper transition is completed. The company has begun an external search for his replacement and expects Dr. Dolsten to stay with the company until at least February 28, 2025. This transition was reported in a Form 8-K filed with the SEC, dated July 9, 2024, with the report signed the following day by Margaret M. Madden, Senior Vice President and Corporate Secretary of Pfizer.
Pfizer Inc. has announced the commencement of a search for a new Chief Scientific Officer as Dr. Mikael Dolsten, the current Chief Scientific Officer and President of Pfizer Research & Development, prepares to step down. Dr. Dolsten, who has had a notable career spanning over 15 years at Pfizer, will remain in his role until a successor is appointed and a proper transition is completed. The company has begun an external search for his replacement and expects Dr. Dolsten to stay with the company until at least February 28, 2025. This transition was reported in a Form 8-K filed with the SEC, dated July 9, 2024, with the report signed the following day by Margaret M. Madden, Senior Vice President and Corporate Secretary of Pfizer.
輝瑞公司宣佈開始尋找新的首席科學官,現任首席科學官和研發總裁Mikael Dolsten博士準備辭職。Dolsten博士在輝瑞公司的傑出職業跨足了15多年,他將在接任者被任命並完成適當的過渡之前繼續擔任該職位。公司已經開始外部搜索他的繼任者,預計Dolsten博士將至少留在公司直到2025年2月28日。這一過渡在一份提交給美國證券交易委員會的8-k文件中報道,文件於2024年7月9日簽署,簽署者是輝瑞公司高級副總裁兼公司秘書Margaret m. Madden。
輝瑞公司宣佈開始尋找新的首席科學官,現任首席科學官和研發總裁Mikael Dolsten博士準備辭職。Dolsten博士在輝瑞公司的傑出職業跨足了15多年,他將在接任者被任命並完成適當的過渡之前繼續擔任該職位。公司已經開始外部搜索他的繼任者,預計Dolsten博士將至少留在公司直到2025年2月28日。這一過渡在一份提交給美國證券交易委員會的8-k文件中報道,文件於2024年7月9日簽署,簽署者是輝瑞公司高級副總裁兼公司秘書Margaret m. Madden。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息